22.8 C
New York
Sunday, August 17, 2025

Tag: recruitment

SRPT IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important...

NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options

Ryght AI Partners with Global CRO Biorasi to Deliver AI-Powered Feasibility Solutions to Biotech and Biopharma Sponsors

Advanced AI Platform Enables More Accurate Site Selection and Faster Study Startup Across Key Therapeutic Areas Partnership brings real-time site identification, feasibility, activation and automated...

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) and certain of its officers.

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

NANO Nuclear Reports Third Fiscal Quarter 2025 Financial Results and Provides Business Update

New York, N.Y., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today reported its third fiscal quarter financial results and provided a business update.

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts...

Lumen Launches “The Talent Frontier” — A Webcast Series to Rethink Recruitment with Clarity, Empathy and Strategy

MELBOURNE, Australia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lumen has launched “The Talent Frontier,” a webcast series exploring innovative recruitment marketing and talent acquisition strategies to transform hiring. The inaugural session “AI for All: Rethinking Talent with Equity, Empathy & Automation,” sets the stage for diverse and inclusive topics in future sessions.

Mattr Announces Second Quarter 2025 Results

TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) reported today its operational and financial results for the three and six months ended June 30, 2025. This press release should be read in conjunction with the Company’s Management Discussion and Analysis (“MD&A”) and interim consolidated financial statements for the six months ended June 30, 2025, which are available on the Company’s website and at www.sedarplus.ca.

ACLS Launches New Doctoral Futures Initiative to Assess and Reimagine Humanities Graduate Education

Three Year Collaboration with the American Historical Association, the Modern Language Association, and the Society of Biblical Literature Aims to Identify and Introduce New...

HopeAI Showcases AI-Powered Synthetic Data to Speed Up Cancer Drug Trials at ASCO 2025

NEW YORK, Aug. 13, 2025 /PRNewswire/ -- HopeAI , a Mayo Clinic Platform Accelerate company, is advancing how cancer clinical trials are designed and...

Star Equity Holdings, Inc. Announces 2025 Second Quarter Financial Results

Q2 2025 revenues increased ~76% to $23.7 million and gross profit increased ~182% to $6.3 million

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRecruitment